PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03763643 |
|
Recruitment Status :
Recruiting
First Posted : December 4, 2018
Last Update Posted : February 8, 2023
|
Sponsor:
University of Minnesota
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
University of Minnesota
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 31, 2023 |
| Estimated Study Completion Date : | December 31, 2024 |